Literature DB >> 16928339

Cardiac amyloidosis: shifting our impressions to hopeful.

Douglas B Sawyer1, Martha Skinner.   

Abstract

Cardiac amyloidosis is a well-known but clinically rare cause of heart failure that has historically been associated with a poor prognosis. Cardiac amyloidosis involves fibril formation from one of several underlying conditions, and the course of illness and prognosis varies among these conditions. Evolving treatment strategies for patients with primary systemic amyloidosis have given this subset of cardiac amyloidosis patients a cause for hope. The identification and appropriate referral of patients in whom this condition is suspected will help to improve the likelihood of successful therapy and long-term survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928339     DOI: 10.1007/s11897-006-0004-z

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  41 in total

1.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Joseph P McConnell; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; William J Hogan; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Christopher G A McGregor; Allan S Jaffe
Journal:  Blood       Date:  2004-03-25       Impact factor: 22.113

2.  Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy.

Authors:  E A Pomfret; W D Lewis; R L Jenkins; P Bergethon; S W Dubrey; J Reisinger; R H Falk; M Skinner
Journal:  Transplantation       Date:  1998-04-15       Impact factor: 4.939

3.  Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes.

Authors:  S W Dubrey; K Cha; M Skinner; M LaValley; R H Falk
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

4.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

5.  Holter monitoring in AL amyloidosis: prognostic implications.

Authors:  G Palladini; G Malamani; F Cò; A Pistorio; F Recusani; E Anesi; P Garini; G Merlini
Journal:  Pacing Clin Electrophysiol       Date:  2001-08       Impact factor: 1.976

6.  Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.

Authors:  R Liao; M Jain; P Teller; L H Connors; S Ngoy; M Skinner; R H Falk; C S Apstein
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

7.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

Review 8.  Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.

Authors:  Walid Hassan; Hani Al-Sergani; Walid Mourad; Rashed Tabbaa
Journal:  Tex Heart Inst J       Date:  2005

9.  Heart transplantation in patients with amyloidosis: single-center experience.

Authors:  A Alloni; C Pellegrini; T Ragni; C Goggi; A M D'Armini; M Rinaldi; M Viganò
Journal:  Transplant Proc       Date:  2004-04       Impact factor: 1.066

10.  Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation.

Authors:  S Dubrey; A Pollak; M Skinner; R H Falk
Journal:  Br Heart J       Date:  1995-11
View more
  5 in total

1.  Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy.

Authors:  Michael J Greene; Flora Sam; Pamela T Soo Hoo; Rupesh S Patel; David C Seldin; Lawreen H Connors
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

2.  Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.

Authors:  Jacquelyn L S Hanson; Marios Arvanitis; Clarissa M Koch; John L Berk; Frederick L Ruberg; Tatiana Prokaeva; Lawreen H Connors
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790

3.  Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.

Authors:  Andreia Biolo; Sujata Ramamurthy; Lawreen H Connors; Carl J O'Hara; Hans K Meier-Ewert; Pamela T Soo Hoo; Douglas B Sawyer; David C Seldin; David S Seldin; Flora Sam
Journal:  Circ Heart Fail       Date:  2008-10-14       Impact factor: 8.790

4.  Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.

Authors:  Lawreen H Connors; Flora Sam; Martha Skinner; Francesco Salinaro; Fangui Sun; Frederick L Ruberg; John L Berk; David C Seldin
Journal:  Circulation       Date:  2015-12-11       Impact factor: 29.690

5.  Cardiac transthyretin amyloidosis 99mTc-DPD SPECT correlates with strain echocardiography and biomarkers.

Authors:  Viktor Löfbacka; Jan Axelsson; Björn Pilebro; Ole B Suhr; Per Lindqvist; Torbjörn Sundström
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-12-26       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.